Many potentially valuable medicines are lost during their development before they are made available to patients. By applying its expertise in pharmacogenomics and identifying the patients most likely to respond well to a medicine, PGXIS will increase the number of these medicines that successfully complete their development and become available for patients. The same approach will also make the medicines more valuable to those organisations that have to pay for healthcare, and so make the medicines more widely available to those who will respond well.